Search

Displaying results 1821 - 1830 of 6831 in total
  1. Drug

    Cinnamyl alcohol

    go.drugbank.com/drugs/DB14186
    Approved

    Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% [A34266]. Sensitivity to cinnamyl alcohol may be identified with a clinical patch test. … Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as [DB14184] within commercial products.

  2. Drug

    Aminohippuric acid

    go.drugbank.com/drugs/DB00345
    ApprovedInvestigationalWithdrawn

    Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

  3. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    [A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.[L48827] … Compared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery

  4. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. … Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms.

  5. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    Concizumab therefore provides an important treatment option for patients who have developed inhibitors to standard clotting factor replacement therapy. … [L51998,L52043] In July 2025, its indication was expanded to include all patients with hemophilia A or B, regardless of the presence of inhibitors.[L53653]

  6. Drug

    Crotalus atrox antivenin

    go.drugbank.com/drugs/DB13892
    Approved

    It is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label]. … The majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F113].

  7. Drug

    Lovastatin

    go.drugbank.com/drugs/DB00227
    ApprovedInvestigational

    [A174580,A181409,A181535,A181538,A1793] Potency is thought to correlate to tissue permeability as the more lipophilic statins such as lovastatin are thought to enter endothelial cells by passive diffusion … [A174550] Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the

  8. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    [A259771] Beremagene geperpavec is genetically modified to deliver _COL7A1_, thereby restoring the levels of the COL7 protein.[L46551] … Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).

  9. Drug

    Gadoxetic acid

    go.drugbank.com/drugs/DB08884
    ApprovedInvestigational

    Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. … A263156] Gadoxetate is a unique gadolinium-based contrasting agent (GBCA) with both dynamic phase and hepatobiliary phase and thus has different pharmacokinetic and pharmacodynamic properties compared to

  10. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and … by the U.S.